Literature DB >> 28454245

Improving contrast enhancement in magnetic resonance imaging using 5-aminolevulinic acid-induced protoporphyrin IX for high-grade gliomas.

Junkoh Yamamoto1, Shingo Kakeda2, Tetsuya Yoneda3, Shun-Ichiro Ogura4, Shohei Shimajiri5, Tohru Tanaka6, Yukunori Korogi2, Shigeru Nishizawa1.   

Abstract

Magnetic resonance imaging (MRI) with a gadolinium-based contrast agent is the gold standard for high-grade gliomas (HGGs). The compound 5-aminolevulinic acid (5-ALA) undergoes a high rate of cellular uptake, particularly in cancer cells. In addition, fluorescence-guided resection with 5-ALA is widely used for imaging HGGs. 5-ALA is water soluble, while protoporphyrin IX (PpIX) is water insoluble. It was speculated whether converting from 5-ALA to PpIX may relatively increase intracellular water content, and consequently, might enhance the T2 signal intensity in HGG. The aim of the present study was to assess whether 5-ALA-induced PpIX enhances the T2 signal intensity in patients with HGGs. A total of 4 patients who were candidates for HGG surgical treatment were prospectively analyzed with preoperative MRI. Patients received oral doses of 5-ALA (20 mg/kg) 3 h prior to anesthesia. At 2.5 h post-5-ALA administration, T2-weighted images (T2WIs) were obtained from all patients. Subsequently, tumors were evaluated via fluorescence using a modified operating microscope. Fluorescent tumor tissues were obtained to analyze the accumulation of 5-ALA-induced PpIX within the tumors, which was confirmed quantitatively by high-performance liquid chromatography (HPLC) analysis. The MRI T2 signal intensity within the tumors was evaluated prior to and following 5-ALA administration. Three glioblastoma multiformes (GBMs) and 1 anaplastic oligodendroglioma (AO) were included in the analysis. Intraoperatively, all GBMs exhibited strong fluorescence of 5-ALA-induced PpIX, whilst no fluorescence was observed in the AO sample. HPLC analysis indicated a higher accumulation of 5-ALA-induced PpIX in the GBM samples compared with the AO sample. In total, 48 regions of interest were identified within the tumors from T2-WIs. In the GBM group, the relative T2 signal intensity value within the tumors following 5-ALA administration was significantly increased compared with the T2 signal intensity value prior to 5-ALA administration (1.537±0.021 and 1.577±0.023, respectively; P=0.0055). No significant differences were observed in the AO group. These results suggest that the 5-ALA-induced PpIX enhanced the T2 signal intensity in HGG. Therefore, 5-ALA may be a potentially useful MRI contrast reagent for HGG.

Entities:  

Keywords:  5-aminolevulinic acid; cancer; contrast reagent; drug repositioning; glioma; magnetic resonance imaging; nephrogenic systemic fibrosis

Year:  2016        PMID: 28454245      PMCID: PMC5403508          DOI: 10.3892/ol.2016.5539

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  50 in total

1.  Transport of 5-aminolevulinic acid between blood and brain.

Authors:  S R Ennis; A Novotny; J Xiang; P Shakui; T Masada; W Stummer; D E Smith; R F Keep
Journal:  Brain Res       Date:  2003-01-10       Impact factor: 3.252

Review 2.  PET in the clinical management of glioma: evidence map.

Authors:  Takashi Nihashi; Issa J Dahabreh; Teruhiko Terasawa
Journal:  AJR Am J Roentgenol       Date:  2013-06       Impact factor: 3.959

3.  Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence.

Authors:  W Stummer; S Stocker; S Wagner; H Stepp; C Fritsch; C Goetz; A E Goetz; R Kiefmann; H J Reulen
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

4.  Prediction of hard meningiomas: quantitative evaluation based on the magnetic resonance signal intensity.

Authors:  Keita Watanabe; Shingo Kakeda; Junkoh Yamamoto; Satoru Ide; Norihiro Ohnari; Shigeru Nishizawa; Yukunori Korogi
Journal:  Acta Radiol       Date:  2015-03-29       Impact factor: 1.990

5.  Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines.

Authors:  Yingbing Wang; Tarik K Alkasab; Ozden Narin; Rosalynn M Nazarian; Rathachai Kaewlai; Jonathan Kay; Hani H Abujudeh
Journal:  Radiology       Date:  2011-05-17       Impact factor: 11.105

6.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

7.  The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis.

Authors:  Yuta Sugiyama; Yuichiro Hagiya; Motowo Nakajima; Masahiro Ishizuka; Tohru Tanaka; Shun-Ichiro Ogura
Journal:  Oncol Rep       Date:  2013-12-23       Impact factor: 3.906

8.  [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.

Authors:  Markus Hutterer; Martha Nowosielski; Daniel Putzer; Nathalie L Jansen; Marcel Seiz; Michael Schocke; Mark McCoy; Georg Göbel; Christian la Fougère; Irene J Virgolini; Eugen Trinka; Andreas H Jacobs; Günther Stockhammer
Journal:  Neuro Oncol       Date:  2013-01-17       Impact factor: 12.300

9.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Malignant glioma: MR imaging by using 5-aminolevulinic acid in an animal model.

Authors:  Hye Rim Cho; Dong Hyun Kim; Daehong Kim; Philip Doble; David Bishop; Dominic Hare; Chul-Kee Park; Woo Kyung Moon; Moon Hee Han; Seung Hong Choi
Journal:  Radiology       Date:  2014-05-12       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.